Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J T Backman

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Clinical Therapeutics|September 28, 2016
Clinical Drug-Drug Interaction Studies: Methods, Pitfalls, and InterpretationJ T Backman
Virchows Archiv : an International Journal of Pathology|September 16, 1998
Immunohistochemical localization of metallothionein in synovial tissue of patients with chronic inflammatory and degenerative joint diseaseJ T Backman, I Siegle, P Fritz
Clinical Pharmacokinetics|July 1, 1997
The role of beta-glucuronidase in drug disposition and drug targeting in humansB Sperker, J T Backman, H K Kroemer
Clinical Pharmacology and Therapeutics|March 30, 2007
Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam--probes of CYP2C9, CYP1A2, and CYP3A4J J Lilja, J T Backman, P J Neuvonen
Clinical Pharmacology and Therapeutics|May 1, 1994
Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazoleK T Olkkola, J T Backman, P J Neuvonen
International Journal of Clinical Pharmacology and Therapeutics|June 1, 1995
Azithromycin does not increase plasma concentrations of oral midazolamJ T Backman, K T Olkkola, P J Neuvonen
Clinical Pharmacology and Therapeutics|January 1, 1996
Rifampin drastically reduces plasma concentrations and effects of oral midazolamJ T Backman, K T Olkkola, P J Neuvonen
Clinical Pharmacology and Therapeutics|April 5, 2012
Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple dosesJ Honkalammi, M Niemi, P J Neuvonen, et al.
The Journal of Antimicrobial Chemotherapy|May 8, 2000
Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failureM Valtonen, E Tiula, J T Backman, et al.
Clinical Pharmacology and Therapeutics|March 4, 2011
Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humansJ Honkalammi, M Niemi, P J Neuvonen, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Clinical Therapeutics|September 28, 2016
Clinical Drug-Drug Interaction Studies: Methods, Pitfalls, and InterpretationJ T Backman
Virchows Archiv : an International Journal of Pathology|September 16, 1998
Immunohistochemical localization of metallothionein in synovial tissue of patients with chronic inflammatory and degenerative joint diseaseJ T Backman, I Siegle, P Fritz
Clinical Pharmacokinetics|July 1, 1997
The role of beta-glucuronidase in drug disposition and drug targeting in humansB Sperker, J T Backman, H K Kroemer
Clinical Pharmacology and Therapeutics|March 30, 2007
Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam--probes of CYP2C9, CYP1A2, and CYP3A4J J Lilja, J T Backman, P J Neuvonen
Clinical Pharmacology and Therapeutics|May 1, 1994
Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazoleK T Olkkola, J T Backman, P J Neuvonen
International Journal of Clinical Pharmacology and Therapeutics|June 1, 1995
Azithromycin does not increase plasma concentrations of oral midazolamJ T Backman, K T Olkkola, P J Neuvonen
Clinical Pharmacology and Therapeutics|January 1, 1996
Rifampin drastically reduces plasma concentrations and effects of oral midazolamJ T Backman, K T Olkkola, P J Neuvonen
Clinical Pharmacology and Therapeutics|April 5, 2012
Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple dosesJ Honkalammi, M Niemi, P J Neuvonen, et al.
The Journal of Antimicrobial Chemotherapy|May 8, 2000
Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failureM Valtonen, E Tiula, J T Backman, et al.
Clinical Pharmacology and Therapeutics|March 4, 2011
Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humansJ Honkalammi, M Niemi, P J Neuvonen, et al.
Pageof 7